Navigating Glioma Treatment: What Korean Research Reveals About Survival
"A new Korean study sheds light on effective treatment strategies for WHO grade II gliomas, offering crucial insights for patients and oncologists."
Low-grade gliomas (LGGs) present a unique challenge in oncology. Unlike more aggressive brain tumors, LGGs, classified as grade I and II by the World Health Organization (WHO), often allow for longer survival, sometimes up to 7 years. However, the optimal treatment approach remains a topic of debate among experts.
Surgery, particularly Gross Total Resection (GTR), where more than 99% of the tumor is removed, is generally considered the first line of treatment. Adjuvant therapies, such as radiotherapy (RT) and chemotherapy, are used to manage any remaining tumor cells and prevent recurrence. The role and timing of these adjuvant treatments, however, are less clear.
To better understand the effectiveness of different treatment strategies, a large intergroup study was conducted in Korea, involving 555 patients diagnosed with WHO grade II LGGs. The study, known as KNOG 15-02 and KROG 16-04, analyzed patient outcomes over a significant follow-up period, providing valuable insights into the impact of various treatment modalities on survival.
Glioma Survival and Real-World Outcomes
Low-grade gliomas generally show more favorable survival than earlier clinical-trial and population-based estimates suggested, according to a comprehensive evaluation of treatment and outcomes. Research on survival in the United States has examined demographic characteristics, initial treatment, and emerging patient and tumor genotypes. Glioblastoma remains the most common brain tumor originating in adults, but published trial populations may be younger and fitter than real-world patients. A real-world study evaluated outcomes in 490 patients with glioblastoma.
Established Care and Its Limits
Current low-grade glioma management includes surgical resection, chemotherapy, and radiation, while newer approaches include targeted therapies. However, radiology-based diagnosis may not fully identify low-grade gliomas or their molecular alterations, and recurrence assessment remains challenging. These limitations create a need for noninvasive diagnostic methods and improved ongoing surveillance. Treatment and prognosis resources continue to describe diagnosis, treatment options, and expected outcomes for low-grade glioma.
Key Findings: Surgery, Chemotherapy, and Radiotherapy
The Korean study, published in the Journal of Neuro-Oncology, meticulously reviewed the medical records of 555 patients diagnosed with WHO grade II LGG between 2000 and 2010. These patients, treated across 14 institutions, were followed for a median of 83.4 months.
- Gender and Age: Male patients and older patients generally experienced poorer survival rates.
- Performance Status: Patients with poorer performance status at the time of diagnosis had reduced survival outcomes.
- Tumor Location: Tumors involving multiple lobes of the brain were associated with poorer survival compared to those confined to a single lobe.
- Histology: Astrocytoma histology was linked to poorer survival outcomes compared to other LGG subtypes like oligodendroglioma and oligoastrocytoma.
Evolving Low-Grade Glioma Management
The Korean Brain Tumor Society consensus review presents practical recommendations for glioma management in Korea and describes its guidance as temporarily useful while evidence accumulates under the new classification system. Recent reviews characterize low-grade glioma as WHO grade 2 disease affecting both pediatric and adult patients, with potential effects on neurologic function and survival. Traditionally, low-grade glioma treatment mirrored approaches used for higher-grade tumors such as glioblastoma. Newer reviews examine current and emerging treatment options for these tumors.
Uncertain Benefits and Confounding
The effect of BRAF-targeted therapy on overall survival in low-grade glioma remains uncertain, although a retrospective cohort reported improved survival with targeted therapy in high-grade glioma. A meta-analysis of 22 case-control series found a slight increase in risk associated with cell-phone use, but potential confounding factors and the study design limit interpretation. In a Korean intergroup study, the radiotherapy group had poorer patient and tumor characteristics than the non-radiotherapy group. The potential overall-survival benefit of adjuvant radiotherapy therefore requires prospective testing.
Clinical Implications and Future Directions
This Korean study underscores the importance of GTR in the management of LGGs. It also suggests that adjuvant chemotherapy may enhance PFS, while the role of adjuvant RT requires careful consideration due to potential confounding factors. The study highlights the need for personalized treatment strategies based on individual patient and tumor characteristics. As molecular diagnostics become more integrated into glioma classification, future clinical trials should focus on tailoring treatments based on molecular biomarkers to optimize outcomes for LGG patients.
Personalized Treatment Decisions
A systematic review and meta-analysis describes optimum low-grade glioma management as controversial, with widespread variation in practice. It evaluated associations between extent of resection, radiation, chemotherapy, mortality, and progression-free survival at 2, 5, and 10 years. Current expert guidance identifies maximal safe tumor resection as an important first step. Postoperative care may involve surveillance, IDH or BRAF inhibitors, radiation, chemotherapy, or combinations selected according to patient- and disease-specific factors.
Beyond Surgery
Recent treatment developments include advances in surgery, chemotherapy, radiation, and targeted therapies for low-grade glioma. Surgery remains a cornerstone of management, but additional therapies may be needed to address recurrence and reduce progression risk. A 2036 glioma market outlook identifies high-grade gliomas, particularly glioblastoma, as continuing to dominate because of high unmet need and poor survival outcomes. The same outlook notes recent approvals in molecularly defined low-grade glioma.
Progress Amid Practice Variation
Low-grade gliomas account for approximately 16.9% to 22% of all primary brain tumors, according to a systematic review. Management generally consists of surgery, sometimes followed by radiation or chemotherapy. A 2024 analysis examined how low-grade glioma survival outcomes have changed over five decades using glioma registry datasets and WHO-defined histopathological groups. The analysis reflects continuing advances in neurosurgical planning, approaches, and practice while highlighting the importance of evaluating long-term survival trends.
What Treatment Means for Patients
A single-center retrospective case series studied adult patients with pathologically confirmed WHO grade II glioma diagnosed between 2009 and 2018. The study collected demographic, clinical, and pathologic data, illustrating how real-world evidence can complement broader treatment research. Diffuse low-grade glioma includes astrocytoma IDH-mutant and oligodendroglioma IDH-mutant 1p19q-codeleted subtypes. Even after resection, tumor cells may remain and contribute to regrowth.